Physician

Anesthesiology

Dr. Piotr S. Rutkowski, MD

Piotr Rutkowski is an expert in the field of Anesthesiology. He attended Medical College of Wisconsin Affiliated Hospitals. Piotr S. Rutkowski is a published doctor and has 35 publications published. The lastest was: 'Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.'

Publications

Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST.
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase ...
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomi...
Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.
Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.
Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
Cutaneous melanoma with nodal metastases in elderly people.
Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.
Melanoma without a detectable primary site with metastases to lymph nodes.
[Biomarkers of alcohol abuse. Part II. New biomarkers and their interpretation].
Oncogenic osteomalacia associated with phosphaturic mesenchymal tumour, mixed connective tissue type of the knee.
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone.
Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression.
Epidermal growth factor receptor (EGFR) status in chordoma.
Influence of zinc chloride addition on the chemical structure of bio-oil obtained during co-pyrolysis of wood/synthetic polymer blends.
Her2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment.
Other targetable sarcomas.
Emergency surgery in the era of molecular treatment of solid tumours.
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 pa...
Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.
The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Bresl...
Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas.

Doctors Specialties

Anesthesiology

Accepted Insurances

Education

Medical College of Wisconsin Affiliated Hospitals
Jagiellonian University Medical College

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Roger A. Fons, MD This Doctor is OpenDoctor Recommended.
	Dr. Gregory A. Felsheim, MD This Doctor is OpenDoctor Recommended.
	Dr. George Brodzinski, MD This Doctor is OpenDoctor Recommended.
	Dr. James R. Ducanto, MD This Doctor is OpenDoctor Recommended.
	Dr. Roman Berezovski, MD This Doctor is OpenDoctor Recommended.
	Dr. Dorothea Hall, MD This Doctor is OpenDoctor Recommended.
	Dr. Alan H. Goldberg, MD
	Dr. Susan Taylor, MD
	Dr. Timothy W. Walton, MD This Doctor is OpenDoctor Recommended.
	Dr. Jurica Bajic, MD This Doctor is OpenDoctor Recommended.
	Dr. Timothy J. Glendenning, MD
	Dr. Jennifer S. Kickendahl, MD This Doctor is OpenDoctor Recommended.